Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: Findings from cohort C of the OPAL phase 2 trial
Study limitation reported by the research below: “Trial was stopped early for futility with only 36 of a planned larger cohort enrolled, substantially limiting power and the reliability of safety comparisons.”